Inventor · disambiguated record
William E. Fogler
Also filed as: FOGLER WILLIAM · FOGLER WILLIAM E
7 granted patents·18 pending applications·171 citations·filing 1999–2023
84Inventor score
Files withGLYCOMIMETICS INC11INTREXON CORP5CHILDRENS MEDICAL CENTER2FOGLER WILLIAM E2ROETH JEREMIAH F2
Top patents by PatentIndex Score
25 records- 0196US6673828B1Analogs of 2-Phthalimidinoglutaric acidCHILDRENS MEDICAL CENTER·Filed 1999·Granted Jan 6, 2004·110 cites·19 claims
- 0292US7112602B2Methods of treating undesired angiogenesis with 2-methyl-EM-138CHILDRENS MEDICAL CENTER·Filed 2003·Granted Sep 26, 2006·30 cites·2 claims
- 0387US9402919B2Vectors conditionally expressing proteinROETH JEREMIAH F·Filed 2012·Granted Aug 2, 2016·28 cites·28 claims
- 0482US11712446B2Methods of mobilizing marrow infiltrating lymphocytes and uses thereofGLYCOMIMETICS INC·Filed 2018·Granted Aug 1, 2023·1 cites·14 claims
- 0577US10584351B2Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereofINTREXON CORP·Filed 2017·Granted Mar 10, 2020·2 cites·30 claims
- 0672US2023414642A1Methods of mobilizing marrow infiltrating lymphocytes and uses thereofGLYCOMIMETICS INC·Filed 2023·Application pending·0 cites
- 0769US2023127765A1Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4GLYCOMIMETICS INC·Filed 2022·Application pending·0 cites
- 0864US2020239906A1Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereofINTREXON CORP·Filed 2020·Application pending·0 cites
- 0960US11433086B2Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4GLYCOMIMETICS INC·Filed 2017·Granted Sep 6, 2022·0 cites·12 claims
- 1059US2024269157A1Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targetingGLYCOMIMETICS INC·Filed 2022·Application pending·0 cites
- 1157US2023364277A1E-selectin targeting agentsGLYCOMIMETICS INC·Filed 2021·Application pending·0 cites
- 1255US2023165882A1Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesisMAGNANI JOHN L·Filed 2021·Application pending·0 cites
- 1353US2023218649A1Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targetingGLYCOMIMETICS INC·Filed 2021·Application pending·0 cites
- 1453US2018344876A1Vectors Conditionally Expressing ProteinINTREXON CORP·Filed 2018·Application pending·0 cites
- 1552US2022257775A1Use of highly potent multimeric e-selectin antagonists for treating sickle cell diseaseGLYCOMIMETICS INC·Filed 2020·Application pending·0 cites
- 1652US2022265693A1Use of e-selectin antagonists to enhance the survival of reconstituted, bone marrow-depleted hostsGLYCOMIMETICS INC·Filed 2020·Application pending·0 cites
- 1751US2023147312A1Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectinGLYCOMIMETICS INC·Filed 2021·Application pending·0 cites
- 1850US2016208285A1Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses ThereofINTREXON CORP·Filed 2015·Application pending·0 cites
- 1948US2013195800A1Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses ThereofROETH JEREMIAH F·Filed 2011·Application pending·0 cites
- 2048US2007185069A1Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agentsPLUM STACY M·Filed 2006·Application pending·0 cites
- 2146US2016317678A1Vectors Conditionally Expressing ProteinINTREXON CORP·Filed 2016·Application pending·0 cites
- 2245US2022265691A1Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor typesGLYCOMIMETICS INC·Filed 2020·Application pending·0 cites
- 2339US2010113404A1Anti-angiogenic activity of 2-methoxyestradiol analogs in combination with anti-cancer agentsLAVALLEE THERESA·Filed 2008·Application pending·0 cites
- 2433US8399440B2Disease modifying anti-arthritic activity of 2-methoxyestradiolFOGLER WILLIAM E·Filed 2007·Granted Mar 19, 2013·0 cites·8 claims
- 2529US2006116360A1Method of administering anti-angiogenic agents and a method of treating disease using sameFOGLER WILLIAM E·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when William E. Fogler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →